Fintel reports that on December 11, 2025, Bernstein initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Outperform ...
BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong ...
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
TipRanks on MSN
BridgeBio initiated with an outperform at Bernstein
Bernstein initiated coverage of BridgeBio (BBIO) with an Outperform rating and $94 price target The firm believes expectations for Attruby are ...
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product ...
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...
Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...
Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle’s disappointing earnings after the ...
Bernstein analyst William Pickering initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO) with an Outperform rating and announced a price target of $94. BridgeBio Pharma shares closed at $72.70 on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback